Concepts (45)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 4 | 2015 | 139 | 0.380 |
Why?
|
| Glioblastoma | 4 | 2015 | 158 | 0.350 |
Why?
|
| Brain Neoplasms | 2 | 2015 | 308 | 0.280 |
Why?
|
| Neurosurgical Procedures | 1 | 2005 | 99 | 0.220 |
Why?
|
| Glioma | 1 | 2005 | 98 | 0.220 |
Why?
|
| Neurosurgery | 1 | 2022 | 29 | 0.190 |
Why?
|
| Societies, Medical | 1 | 2022 | 376 | 0.160 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2015 | 14 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 2167 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2012 | 185 | 0.090 |
Why?
|
| Lectins | 1 | 2011 | 41 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 205 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2011 | 187 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 212 | 0.080 |
Why?
|
| Stereotaxic Techniques | 1 | 2005 | 29 | 0.060 |
Why?
|
| Neurosurgeons | 1 | 2022 | 5 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1146 | 0.050 |
Why?
|
| New England | 1 | 2022 | 273 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2022 | 171 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 659 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2022 | 231 | 0.040 |
Why?
|
| Leadership | 1 | 2022 | 206 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1348 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 422 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 1465 | 0.030 |
Why?
|
| Humans | 6 | 2022 | 63283 | 0.030 |
Why?
|
| Cinnamates | 1 | 2012 | 9 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 203 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 233 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 453 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 190 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2011 | 32 | 0.020 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Adipokines | 1 | 2011 | 30 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 77 | 0.020 |
Why?
|
| Animals | 3 | 2015 | 20634 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 229 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 201 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 893 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 850 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1168 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 922 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 3033 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 10827 | 0.010 |
Why?
|